Gates vets at Adjuvant back Codagenix's software-driven approach to recoding RSV, flu, oncolytic viruses and more
Software is eating the way we make vaccines, and it has earned Farmingdale, NY-based biotech $20 million for a platform tech theoretically applicable to any virus — from influenza to oncolytic viruses targeted at cancer.
Adjuvant Capital, the group of Gates Foundation veterans out to test a VC model for global health, led the Series B for Codagenix. Existing backers Euclidean Capital and Topspin Partners also returned for more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.